Business
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 Gilead Sciences exercised its option to exclusively license KT-200, a first-in-
About this update from Kymera Therapeutics, Inc.
[{"type":"image","alt":"Kymera Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kymera Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/c6ae18a40a38445654545584ae5e2b38"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dnIr_XVqx3Qx7MoOqux__g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3/https://media.zenfs.com/en/globenewswire.com/c6ae18a40a38445654545584ae5e2b38","width":300,"height":69}},"lazy":false},{"type":"text","content":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively","length":160,"tagName":"p"},{"type":"text","content":"FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis ","length":177,"tagName":"p"},{"type":"text","content":"KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 ","length":81,"tagName":"p"},{"type":"text","content":"Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027","length":181,"tagName":"p"},{"type":"text","content":"Well-capitalized with $1.55 billion in cash as of March 31, 2026, and runway into 2029 ","length":86,"tagName":"p"},{"type":"text","content":"Company to hold video conference call and webcast today at 8:30 a.m. ET","length":71,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the first quarter ended March 31, 2026, and provided business highlights and updates on its pipeline.","length":368,"tagName":"p"},{"type":"text","content":"“As we continue to advance KT-621 and KT-579 through clinical development, our focus remains on disciplined execution and delivering on multiple important milestones this year,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “We remain committed to translating our first-in-class science into bette...